A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma.

Abstract	Recent evidence suggests that the vasopressin analogue desglycinamide-arginine8-vasopressin (DGAVP) might specifically benefit mild brain trauma patients. We investigated the effect of intranasal DGAVP treatment in 32 patients who had sustained a mild head injury for 3 months in a double-blind, placebo-controlled, matched-pairs study. DGAVP did not have a positive effect on cognitive recovery in this group of mildly affected patients.
Authors	N I Bohnen, A Twijnstra, J Jolles
Journal	Neurology (Neurology) Vol. 43 Issue 1 Pg. 103-6 (Jan 1993) ISSN: 0028-3878 [Print] United States
PMID	8423870 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References	Arginine Vasopressin argipressin, des-GlyNH2(9)-
Topics	Adolescent Adult Aged Arginine Vasopressin (analogs & derivatives, therapeutic use) Cognition Disorders (drug therapy, etiology) Craniocerebral Trauma (complications) Double-Blind Method Female Humans Male Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!